These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 33157077)

  • 21. Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU):: The Phase 2 SATURN Study.
    Heissigerová J; Callanan D; de Smet MD; Srivastava SK; Karkanová M; Garcia-Garcia O; Kadayifcilar S; Ozyazgan Y; Vitti R; Erickson K; Athanikar A; Chu K; Saroj N; Sundaram PA; Varona R; Corp-Dit-Genti V; Buggage R; Cheng Y; Soo Y; Nguyen QD
    Ophthalmology; 2019 Mar; 126(3):428-437. PubMed ID: 30316888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
    ; Kempen JH; Altaweel MM; Holbrook JT; Sugar EA; Thorne JE; Jabs DA
    JAMA; 2017 May; 317(19):1993-2005. PubMed ID: 28477440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal Vision-Related Quality of Life for Patients with Noninfectious Uveitis Treated with Fluocinolone Acetonide Implant or Systemic Corticosteroid Therapy.
    Sugar EA; Venugopal V; Thorne JE; Frick KD; Holland GN; Wang RC; Almanzor R; Jabs DA; Holbrook JT;
    Ophthalmology; 2017 Nov; 124(11):1662-1669. PubMed ID: 28624167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program.
    Merrill PT; Clark WL; Banker AS; Fardeau C; Franco P; LeHoang P; Ohno S; Rathinam SR; Ali Y; Mudumba S; Shams N; Nguyen QD;
    Ophthalmology; 2020 Oct; 127(10):1405-1415. PubMed ID: 32564920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of Treating Pediatric Uveitis With Dexamethasone Implants.
    Tomkins-Netzer O; Talat L; Seguin-Greenstein S; Bar A; Lightman S
    Am J Ophthalmol; 2016 Jan; 161():110-5.e1-2. PubMed ID: 26478217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA).
    Nguyen QD; Merrill PT; Clark WL; Banker AS; Fardeau C; Franco P; LeHoang P; Ohno S; Rathinam SR; Thurau S; Abraham A; Wilson L; Yang Y; Shams N;
    Ophthalmology; 2016 Nov; 123(11):2413-2423. PubMed ID: 27692526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.
    Srivastava SK; Watkins TR; Nguyen QD; Sharma S; Scales DK; Dacey MS; Shah RE; Chu DS; Grewal DS; Faia LJ; Suhler EB; Genovese MC; Guo Y; Barchuk WT; Besuyen R; Dick AD; Rosenbaum JT
    JAMA Ophthalmol; 2024 Sep; 142(9):789-797. PubMed ID: 39023880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients.
    Namba K; Kaburaki T; Tsuruga H; Ogawa Y; Iwashita E; Goto H
    Ophthalmol Ther; 2022 Jun; 11(3):1147-1161. PubMed ID: 35305254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
    Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
    Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis.
    Park SE; Jun JW; Lee DH; Lee SC; Kim M
    Yonsei Med J; 2021 Feb; 62(2):177-181. PubMed ID: 33527798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment with infliximab after adalimumab failure in pediatric noninfectious uveitis.
    Ashkenazy N; Saboo US; Abraham A; Ronconi C; Cao JH
    J AAPOS; 2019 Jun; 23(3):151.e1-151.e5. PubMed ID: 31063811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation.
    Schilling H; Heiligenhaus A; Laube T; Bornfeld N; Jurklies B
    Retina; 2005; 25(2):182-8. PubMed ID: 15689809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon-alpha2a and Systemic Corticosteroid in Monotherapy in Chronic Uveitis: Results of the Randomized Controlled BIRDFERON Study.
    Fardeau C; Simon A; Rodde B; Viscogliosi F; Labalette P; Looten V; Tézenas du Montcel S; LeHoang P
    Am J Ophthalmol; 2017 May; 177():182-194. PubMed ID: 28315319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quiescence and Subsequent Anterior Chamber Inflammation in Adalimumab-treated Pediatric Noninfectious Uveitis.
    Choe S; Heo JW; Oh BL
    Korean J Ophthalmol; 2020 Aug; 34(4):274-280. PubMed ID: 32783419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.
    ; Sugar EA; Holbrook JT; Kempen JH; Burke AE; Drye LT; Thorne JE; Louis TA; Jabs DA; Altaweel MM; Frick KD
    Ophthalmology; 2014 Oct; 121(10):1855-62. PubMed ID: 24908205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab: A Review in Non-Infectious Non-Anterior Uveitis.
    Hoy SM
    BioDrugs; 2017 Apr; 31(2):135-142. PubMed ID: 28229433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab for the treatment of refractory noninfectious paediatric uveitis.
    Muñoz-Gallego A; Barral E; Enríquez E; Tejada P; Barceló A; de Inocencio J
    Int Ophthalmol; 2017 Jun; 37(3):719-725. PubMed ID: 27432171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of adalimumab in patients with active non-infectious intermediate, posterior, and panuveitis in real-life clinical practice: HOPE study.
    Pleyer U; Al-Mutairi S; Murphy CC; Hamam R; Hammad S; Nagy O; Szepessy Z; Guex-Crosier Y; Julian K; Habot-Wilner Z; Androudi S
    Br J Ophthalmol; 2023 Nov; 107(12):1892-1899. PubMed ID: 36261259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis.
    Sepah YJ; Sadiq MA; Chu DS; Dacey M; Gallemore R; Dayani P; Hanout M; Hassan M; Afridi R; Agarwal A; Halim MS; Do DV; Nguyen QD
    Am J Ophthalmol; 2017 Nov; 183():71-80. PubMed ID: 28887113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.